Esketamine Enhances the Chemosensitivity of Colorectal Adenocarcinoma Cells to 5-Fluorouracil via AMPK/mTOR/HMMR Signaling Pathway.
Oncology research 2026 Yuerou Feng, Panpan Tong, Shuwen Fu et al.
The efficacy of standard 5-fluorouracil (5-FU) chemotherapy for colorectal cancer is limited by drug resistance and adverse effects, prompting research into esketamine, a potent ketamine variant with analgesic, antidepressant, and recently discovered anti-tumor properties, to determine if it can enhance 5-FU's chemosensitivity. This study investigates whether esketamine synergizes with 5-FU to...
DOI: 10.32604/or.2025.072563 (opens in new tab)
Full text (opens in new tab)
Esketamine
5-fluorouracil
Ampk/mtor/hmmr pathway
Chemosensitivity
+1